Shots:

• EMA accepted the review of MAA for SB11 in Oct 2020. If approved- SB11 will add to the biosimilars portfolio developed by Samsung Bioepis and commercialized by Biogen- including three widely prescribed anti-TNF biosimilars in EU: BENEPALI- IMRALDI- and FLIXABI
• In Nov 2019- Samsung Bioepis entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates- SB11 (ranibizumab) and SB15 (aflibercept)- in the US- Canada- EU- Japan- and Australia
• Ranibizumab is an anti-VEGF therapy for retinal vascular disorders- which is a leading cause of blindness in the US

 ­ Ref: Samsung Bioepis | Image: Biogen